FDA tentatively approves Alembic’s bimatoprost solution

The FDA has issued tentative approval for Alembic Pharmaceuticals’ abbreviated new drug application for bimatoprost ophthalmic solution 0.03%, the company announced in a press release.
Therapeutically equivalent to Allergan’s Latisse, Alembic’s product is indicated for the treatment of hypotrichosis of the eyelashes, the release said.
The launch of the product is contingent upon litigation between the two companies, which is currently underway in the District Court of New Jersey.

Full Story →